These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37644656)

  • 1. Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis?
    Bessette L; Movahedi M; Reed G; Kremer JM; Kane K; Keystone E
    J Clin Rheumatol; 2023 Oct; 29(7):332-340. PubMed ID: 37644656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis.
    Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordström D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jørgensen TS; Jacobsson LTH; Askling J
    J Rheumatol; 2021 Oct; 48(10):1512-1518. PubMed ID: 33649069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi.
    Asante K; Racsa P; Bloomfield A; Cornett D; Schwab P
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1109-1118. PubMed ID: 37776118
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
    Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
    Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset.
    Youssef P; Marcal B; Button P; Truman M; Bird P; Griffiths H; Roberts L; Tymms K; Littlejohn G
    J Rheumatol; 2020 Aug; 47(8):1174-1181. PubMed ID: 31787605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis.
    Baker JF; Reed G; Poudel DR; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1909-1916. PubMed ID: 35143117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.
    Mannion ML; Amin S; Balevic S; Chang ML; Correll CK; Kearsley-Fleet L; Hyrich KL; Beukelman T;
    Arthritis Care Res (Hoboken); 2024 Aug; 76(8):1090-1098. PubMed ID: 38556945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
    Reams J; Berger A; Denio A
    Medicine (Baltimore); 2020 Aug; 99(35):e21827. PubMed ID: 32871905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.